EGFR and glioblastoma: There was also considerable interest in a Phase 3 trial using the antibody-drug conjugate depatuxizumab mafodotin (ABT-414), which binds activated EGFR, in combination with standard-of-care treatment in patients with newly diagnosed, EGFR-amplified glioblastoma.